Rabi Hanna: First-in-Human CRISPR/Cas12a Therapy in Sickle Cell Disease
oncodaily - Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on LinkedIn: “I am excited […]
AI Summary: A first‑in‑human CRISPR/Cas12a therapy for sickle cell disease has treated initial patients, building on preclinical gene‑editing successes that reversed severe disease in models. The advance underscores rapid translation from lab to clinic and renews hope for durable cures—while reminding everyone that the safety and long‑term durability questions remain firmly on the table.
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
Targeted, High-dose Radiation May Improve Treatment for ‘Supermassive’ Bile Duct Tumors
Kathleen Medora / aacr - Patients with very large intrahepatic cholangiocarcinoma experienced improved outcomes when targeted, high-dose radiation was added to chemotherapy PHILADELPHIA – Patients with supermassive intrahepatic cholangiocarcinoma (ICC) benefited from ablative rad…
AI Summary: New clinical reports indicate that targeted high‑dose radiation can improve outcomes for very large “supermassive” bile duct tumors, offering better local control and symptom relief than conventional approaches. Early data suggest this intensity‑modulated strategy may expand options for otherwise difficult‑to‑treat cases, though longer follow‑up is needed to confirm survival benefits.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Memorial Hermann goes out of network with BCBS Texas
Elizabeth Casolo / beckershospitalreview - Houston-based Memorial Hermann Health System’s contract with BCBS Texas expired April 1, rendering the health system out of network. Commercial and ACA exchange (both individual and family) plan members lost access at the end of March. Memorial Hermann ha…
AI Summary: Memorial Hermann and Blue Cross Blue Shield of Texas failed to agree on a new contract, resulting in the health system going out of network for affected plan members. Patients face potential higher costs and care disruptions while negotiators jockey publicly; both sides warn of financial stakes and urge members to stay informed.